Gradual patterned thinning
A widening part, thinner crown, receding temples or a gradual family pattern.
Consultation pathway
Assess miniaturization, then discuss medical therapy, fractional laser and home support when appropriate.
Hair Restoration — Austin
Hair restoration built around the cause, not one device
Grace combines a structured scalp assessment with 1550/1927 fractional laser, medical and home options, and measured follow-up for appropriate thinning. Regrowth is not promised, and some presentations should be referred before treatment.
Initial 4-visit in-office program · $2,499
Medication and home products are individualized and may be separate.
Personalized planStandardized baseline imagingMultiple optionsCentral Austin
Cause before procedure
First: what kind of hair loss does this look like?
People seeking hair loss treatment in Austin may be describing very different conditions. Female hair loss in Austin often presents as a widening part or diffuse thinning, while male pattern hair loss in Austin commonly affects the temples and crown. This framework guides consultation—not diagnosis from a webpage—and sometimes medical evaluation should come first.
Sudden diffuse shedding
Shedding after illness, surgery, major stress, postpartum change, rapid weight loss or a medication change.
Consultation pathway
Identify the trigger and consider medical work-up first. A scalp procedure is not automatically the answer.
Traction or breakage
Loss or breakage in areas exposed to tight styling, repeated tension or mechanical stress.
Consultation pathway
Remove the ongoing cause and assess whether follicles remain viable before planning cosmetic treatment.
Patchy or symptomatic loss
Patches, pain, burning, marked redness or scale, smooth shiny areas, or absent follicular openings.
Consultation pathway
These findings can signal inflammatory, autoimmune or scarring disease. Dermatology or medical evaluation comes first.
Possible medical contributors
Nutrition, thyroid function, hormones, medications and systemic health can affect shedding and density.
Consultation pathway
A targeted medical or laboratory evaluation may matter more than adding another procedure.
How Grace assesses hair loss
Measure → Classify → Plan → Re-measure
No scanner independently diagnoses alopecia. Grace combines the history, repeatable images and scalp findings, then recommends medical review when the presentation falls outside an appropriate cosmetic pathway.
01
Measure
Document the history and establish standardized baseline photographs using consistent angle, part and lighting.
02
Classify
Assess the visible pattern, shaft-caliber variation, follicular openings, scalp condition and signs that warrant referral.
03
Plan
Decide whether the presentation is appropriate for Grace's program and choose only the layers that have a clear role.
04
Re-measure
Repeat the same photos and observations over time rather than relying on memory or day-to-day impressions.
The history matters
What we ask before choosing a treatment
- When the change began and whether it was gradual or sudden
- Family pattern, shedding amount and areas of visible change
- Recent illness, surgery, stress, rapid weight loss or medication changes
- Pregnancy or postpartum timing when relevant
- Styling, traction, scalp symptoms and previous hair treatments
- Medical and laboratory review when indicated—not a universal panel for everyone
When indicated, a medical review may include CBC, iron or ferritin, thyroid testing, or other targeted tests based on history. Not every patient needs every laboratory test.
The Grace Hair Recovery Program
One coordinated plan. Only the layers that make sense.
The program is multimodal because hair loss can have more than one contributor—not because more treatments are automatically better. Each recommendation should have a specific purpose.
Foundation
Address the driver
Correct an identifiable contributor when possible. A procedure cannot substitute for an appropriate medical evaluation.
Usual in-office platform
MultiFrax 1550 / 1927
Grace's usual energy platform for appropriate early-to-moderate patterned thinning, with wavelength and settings selected by the provider.
Post-laser adjunct
ReviveX by Luvigix
Applied topically after fractional laser when appropriate. It is an adjunct—not the primary treatment or a replacement for established medical therapy.
Medical options
Minoxidil / finasteride
Discussed or prescribed when medically appropriate, with route, dose, risks and suitability individualized after evaluation.
Between-visit support
REVIAN RED
An at-home 620/660 nm LED system for consistent photobiomodulation between visits in appropriate androgenetic alopecia.
Emerging option
GHK-Cu
Topical scalp foam or other selected prescribed use may be considered. Human scalp-regrowth evidence remains early and limited.
Selective—not routine
Morpheus8 RF microneedling
Reserved for selected scalp texture or other assessment findings after appropriate evaluation; it is not Grace's default hair platform.
What we are trying to influence
Available option
How it fits
DHT-driven follicle miniaturization
Finasteride when medically appropriate
Established prescription approach for appropriate patients, particularly male-pattern loss.
Shortened or weak growth phase
Minoxidil
Established therapy that requires consistent use and usually months to judge.
Perifollicular remodeling / fractional stimulation
MultiFrax 1550 and/or 1927
Category-level evidence supports similar-wavelength fractional lasers; not a MultiFrax-specific hair-growth claim.
Between-visit photobiomodulation
REVIAN RED
FDA-cleared dual-wavelength home LED device for androgenetic alopecia; an adjunct, not a replacement for medication.
Post-procedure signaling adjunct
ReviveX by Luvigix
Used topically after laser; evidence from broader exosome/EV literature does not prove this product specifically.
Emerging peptide support
GHK-Cu
Optional topical or other selected prescribed use with limited human scalp-regrowth evidence.
Selected scalp texture or assessment findings
Morpheus8 RF microneedling
Considered selectively after evaluation—not for suspected active inflammatory or scarring alopecia.
Fractional laser hair restoration
Why MultiFrax is our main in-office platform
MultiFrax uses 1550 and 1927 nm non-ablative fractional wavelengths, individually or together. Hair research supports these wavelength classes, but the studies below used other devices—not MultiFrax itself. MultiFrax is not FDA-cleared or approved for hair regrowth.
Deeper wavelength
1550 nm
This non-ablative fractional wavelength reaches more deeply than 1927 nm. Small human studies in patterned thinning support the wavelength class, including as an adjunct to minoxidil.
The research used other devices. It does not establish MultiFrax-specific hair-growth results or one universal treatment schedule.
More superficial wavelength
1927 nm
This fractional thulium wavelength works more superficially. Early human research supports further study for patterned thinning and post-laser topical delivery.
The evidence does not prove MultiFrax, ReviveX or Grace's exact protocol. Wavelength and combination are selected after assessment.
Where ReviveX fits
A topical post-laser adjunct—not the foundation
Grace applies ReviveX by Luvigix topically after fractional laser when it is appropriate within the plan. It remains an optional supporting layer rather than the treatment foundation.
Early human exosome and extracellular-vesicle research is promising but limited and varied. Those broader findings do not prove ReviveX specifically. We do not describe it as stem-cell therapy, FDA-approved regenerative medicine or a treatment that “wakes,” regenerates or guarantees follicles.
Transparency: No exosome product is FDA-approved for treating hair loss. Grace presents ReviveX as an adjunct, not a replacement for established medical therapy.
Medication + home support
The work between visits can matter as much as the procedure
Hair biology responds over months. Consistency with an appropriate medical or home plan may contribute more than simply adding another in-office modality.
Established foundation
Minoxidil
An established hair-loss therapy that can reduce loss and support growth or shaft output in appropriate pattern hair loss. It requires consistent use and usually months to assess. Route and dose depend on medical evaluation; Grace does not publish one universal regimen.
Established foundation
Finasteride
A DHT-targeting prescription option for appropriate patients, particularly male-pattern hair loss. It requires medical screening and individualized counseling and is not right for everyone or routinely prescribed to all women.
Supported home adjunct
REVIAN RED
An FDA-cleared at-home 620/660 nm LED system for promoting hair growth in androgenetic alopecia. Company-sponsored clinical research supports its use, with important subset and sponsorship limitations detailed below.
Emerging adjunct
GHK-Cu
Grace may prescribe a topical scalp foam or consider other selected prescribed use. Human scalp-regrowth evidence is weak and early, so GHK-Cu remains an optional adjunct rather than a treatment foundation.
When we use Morpheus8 / microneedling
Selective RF microneedling—not the default
Morpheus8 may be considered for selected scalp texture or other assessment findings after appropriate evaluation. Suspected inflammatory or scarring alopecia remains referral-first and is not presented as a Morpheus8 indication.
Ordinary microneedling
Broader hair-specific evidence
Human studies support ordinary microneedling as an adjunct to minoxidil, though protocols and study quality vary.
Fractional RF microneedling
Smaller supportive evidence
Early research with other fractional RF devices is supportive but limited. It does not prove Morpheus8 specifically or make RF Grace's default hair platform.
Program timeline
Hair biology is slow. The measurement plan should be patient.
No fixed date can promise a visible result. Grace uses checkpoints to evaluate whether the plan is tolerable, consistent and worth continuing.
Week 0
Consultation + baseline
History, consistent photographs and scalp analysis, plus a decision about whether medical or dermatology work-up should come first.
Initial program
Four in-office visits
Usually built around MultiFrax with topical ReviveX when appropriate. Exact wavelength, combination and spacing are individualized.
Between visits
Support the plan
The individualized plan may include minoxidil, finasteride, REVIAN and/or GHK-Cu. These are separate from the four in-office visits unless specifically stated in your plan.
Around 3 months
Check adherence + tolerance
Review consistency, tolerability and photographs without overinterpreting an early checkpoint.
Around 6 months
Formal re-measure
Repeat the baseline views and decide whether to continue, maintain, change strategy or refer.
Long term
Maintain what works
Pattern hair loss commonly requires ongoing successful medical or home therapy to help preserve benefit.
Candidacy
Who this program is for—and who it is not for
Often a good fit
- Early-to-moderate patterned thinning
- Visible existing follicles
- Realistic expectations
- Willingness to follow a months-long plan
Evaluate or refer first
- Sudden heavy shedding or patchy loss
- Possible active inflammatory or scarring disease
- Unexplained pain, burning, marked scale or infection
- Findings suggesting a medical diagnosis should come first
A transplant may be more appropriate
- Advanced smooth bald areas
- Long-established complete follicle loss
- Limited expected upside from non-surgical stimulation
- Need for a surgical-restoration opinion
Evidence, translated
What the evidence actually supports
This is not a numeric ranking. It is a plain-language view of how mature the evidence is for each layer of the program.
Established foundations
Minoxidil · finasteride for appropriate male-pattern hair loss
Longstanding medical options with stronger clinical support, medical screening and ongoing-use considerations.
Supported adjuncts
Low-level light / LED · fractional laser · microneedling
Human clinical evidence supports a role, but devices, protocols, study quality and patient selection vary.
Emerging adjuncts
Exosome / EV products · GHK-Cu
Interesting early signals, but limited or heterogeneous human evidence. They should not displace established therapy.
See the research
Study details remain available here with direct sources. Research on a wavelength class, ingredient category or another device does not prove Grace's exact platform, product or protocol.
1550 nm fractional laser studies
A 2011 single-arm study enrolled 28 women (27 completed) for ten treatments every two weeks; mean density changed from 100±14 to 157±28 hairs/cm² and mean thickness from 58±12 to 75±13 µm at five months. A 2018 uncontrolled study of 23 patients used twelve sessions every two weeks and reported increased count and shaft diameter. A 2019 randomized, investigator-blinded split-scalp trial in 30 men found 1550 nm fractional laser plus topical 5% minoxidil outperformed minoxidil alone at 24 weeks. These small studies used other devices and do not establish MultiFrax-specific efficacy.
1927 nm fractional laser studies
A 2018 evaluator-blinded split-scalp study in 10 patients used twelve weekly sessions. Laser alone increased density and thickness, while a post-laser growth-factor solution showed additional improvement. A 2026 meta-analysis included 15 studies and 1,097 patients and found improved density across fractional laser therapy, without a statistically significant difference among 1550, 1565 and 1927 nm subgroups. The studies were heterogeneous: they support wavelength-class research, not MultiFrax, ReviveX or Grace's exact protocol.
Microneedling and RF evidence
A 2025 meta-analysis of 12 randomized trials and 631 patients found ordinary microneedling plus minoxidil improved hair count versus minoxidil alone, with substantial heterogeneity. A separate randomized split-scalp study of 19 men reported improved count and thickness after five monthly fractional-RF sessions plus 5% minoxidil. That RF study used another device and does not prove Morpheus8 specifically.
REVIAN RED study context
In a company-sponsored randomized, sham-controlled multicenter study of 81 enrolled subjects, the smaller protocol-defined highly compliant efficacy group showed a 26.3 hairs/cm² advantage over sham at 16 weeks. The subset analysis and sponsorship limit how broadly that figure should be interpreted.
ReviveX, exosome/EV and GHK-Cu limitations
A 2025 review identified 11 small and heterogeneous clinical studies of exosome or extracellular-vesicle approaches, including two randomized trials. Those findings do not prove ReviveX specifically, and no exosome product is FDA-approved for hair loss. Human scalp-regrowth evidence for GHK-Cu remains weak and early; selective prescribed use is not presented as equivalent to established medication, and no dosing or injection protocol is published here.
Hair restoration questions
Clear answers before you commit
Hair Restoration Consultation
Measure first. Then decide what is worth treating.
Start with a structured assessment of the pattern, history and scalp findings. If Grace's program is appropriate, your plan will identify which in-office, medical and home layers have a reason to be there.
Visit
Northland Drive, Central Austin
Grace MedSpa and Body Solutions treats patients from one Austin location, convenient to Northwest Hills, Allandale, Rosedale and the Domain. Patients also visit from West Lake Hills and Lakeway.
Hours
- Monday – Friday
- 9:00 AM – 5:00 PM
- Saturday – Sunday
- Closed